Skyelarke Announces New Enhancements to Patient Payment Platform, SkyePay
Skyelarke has announced new additions to SkyePay, a patient payment technology.
With the launch of faster payments via bank transfer, virtual cards, and PayPal/Venmo integration, on top of the physical card option, SkyePay is now providing patients with more options around how they receive their expense or stipend payments related to clinical trial participation.
In addition to increased patient payment choice, SkyePay has also developed an API framework, soon to be released, which will allow IRT, EDC, or ePRO integration.
Key benefits of the SkyePay platform include:
- For patients: automated and fast payments, multiple payment methods (bank transfer, card, and virtual), and reduced financial burden.
- For sites: no training required, ability to make fast payments, integrated receipt management, and sponsor/CRO approval process.
- For sponsors/CROs: transaction reporting for reconciliation purposes, fast approval processes, and privacy by design with data stored depending on where the study is.
Reference
Skyelarke furthers its mission to break down barriers to clinical trial participation, with new SkyePay enhancements. (2023, July 11). Cision PR Newswire.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
